Previous 10 | Next 10 |
Provides U.S. Patent Protection to at least August 2038 Expands Patent Protection for FS118 Composition of Matter beyond Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-sta...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next-generation bispecific immunotherapies to transform the lives of patients with cancer, today ann...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today ann...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 07, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today ann...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today ann...
The following slide deck was published by F-star Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: F-star Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation
F-star Therapeutics, Inc. (FSTX) Q3 2021 Earnings Conference Call November 10, 2021, 09:00 AM ET Company Participants Lindsey Trickett - VP of IR Eliot Forster - CEO Darlene Deptula-Hicks - CFO Conference Call Participants Hartaj Singh - Oppenheimer & Co. Daina Graybosch - SVB Leerink Jus...
Dr. Michelle Morrow to present on F-star’s Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific Poster Presentation of Preclinical Data Demonstrates Potential for F-star’s FS120 First-in-Class OX40/CD137 Tetravalent Dual T Cell Agonist in...
DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. , a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Darlene Deptula–Hicks, Chief Financial Officer of F-star The...
News, Short Squeeze, Breakout and More Instantly...
F-star Therapeutics Inc Com Company Name:
FSTX Stock Symbol:
NASDAQ Market:
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWI...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to t...
LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statemen...